My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Wave Life Sciences Ltd. - Ordinary Shares (NQ:WVE)

12.65 -0.15 (-1.17%)

Streaming Delayed Price Updated: 3:08 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Wave Life Sciences Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >

Crude Oil Falls Over 2%; Campbell's Earnings Top Estimates ↗

September 03, 2025

Via Benzinga

Wednesday's session: gap up and gap down stocks ↗

September 03, 2025

Today's session on Wednesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

Nasdaq Gains Over 100 Points; Dollar Tree Post Upbeat Earnings ↗

September 03, 2025

Via Benzinga

Which stocks are moving before the opening bell on Wednesday? ↗

September 03, 2025

Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.

Via Chartmill

Earnings Scheduled For July 30, 2025 ↗

July 30, 2025

Via Benzinga

Insights into WAVE Life Sciences's Upcoming Earnings ↗

July 29, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 03, 2025

Via Benzinga

This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

August 04, 2025

Via Benzinga

Beyond The Numbers: 6 Analysts Discuss WAVE Life Sciences Stock ↗

August 04, 2025

Via Benzinga

Wave (WVE) Q2 Revenue Drops 56% ↗

July 31, 2025

Via The Motley Fool

Wave Life Sciences Ltd (NASDAQ:WVE) Reports Q2 2025 Earnings: Revenue Miss but Narrower Loss and Clinical Progress Boost Shares ↗

July 30, 2025

Wave Life Sciences Q2 2025 results show $8.7M revenue miss but narrower EPS loss. Stock rises on optimism for WVE-006's AATD clinical progress.

Via Chartmill

WAVE Life Sciences Earnings Preview ↗

May 07, 2025

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

What's Next: WAVE Life Sciences's Earnings Preview ↗

November 11, 2024

Via Benzinga

This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

July 28, 2025

Via Benzinga

Breaking Down WAVE Life Sciences: 4 Analysts Share Their Views ↗

July 16, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 10, 2025

Via Benzinga

Where WAVE Life Sciences Stands With Analysts ↗

June 23, 2025

Via Benzinga

The Analyst Verdict: WAVE Life Sciences In The Eyes Of 4 Experts ↗

April 29, 2025

Via Benzinga

Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year ↗

March 26, 2025

Wave Life plans a 2026 NDA filing for WVE-N531 after positive Phase 2 data in Duchenne muscular dystrophy, showing functional gains and biomarker improvements.

Via Benzinga

Earnings Scheduled For March 4, 2025 ↗

March 04, 2025

Via Benzinga

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

February 25, 2025

Via Benzinga

1 Brand-New Big Reason to Buy This Biotech Stock Right Now ↗

October 24, 2024

This stock currently has a good balance of risk and potential rewards.

Via The Motley Fool

Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space. ↗

October 21, 2024

Korro Bio is lagging Wave Life Sciences. But an analyst says it could ultimately be the leader.

Via Investor's Business Daily

Oklo, CleanSpark And Wolfspeed Are Among Top 7 Mid Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio? ↗

October 20, 2024

These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio?

Via Benzinga

This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗

October 16, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 16, 2024

Via Benzinga

Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans ↗

October 16, 2024

Wave Life Sciences' WVE-006 demonstrates first-ever RNA editing in humans for alpha-1 antitrypsin deficiency, showing favorable safety and efficacy in early trial results. GSK holds global license...

Via Benzinga

Wave Life Sciences Just Edited RNA — And Shares Hit The Stratosphere ↗

October 16, 2024

The company is testing its new technology in patients with a genetic disease that impacts the lungs.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.